Literature DB >> 9426691

Combinations of paclitaxel and vinblastine and their effects on tubulin polymerization and cellular cytotoxicity: characterization of a synergistic schedule.

P Giannakakou1, L Villalba, H Li, M Poruchynsky, T Fojo.   

Abstract

Paclitaxel (PTX) and vinblastine (VBL) represent 2 classes of drugs that target tubulin but have separate binding properties and opposing mechanisms of action. To evaluate the potential use of these agents together in a chemotherapeutic regimen, we investigated their effects on the dynamics of tubulin polymerization and cellular cytotoxicity, when administered singly or in combination. In human epidermoid carcinoma KB cells and MCF-7 breast carcinoma cells, we observed a time- and dose-dependent effect on cytoskeletal dynamics for both PTX and VBL. Tubulin polymerization induced by PTX was stable for more than 24 hr. When PTX treatment was followed by VBL, a time- and dose-dependent reversal of tubulin polymerization was observed. In contrast, rapid tubulin polymerization occurred when VBL was followed by PTX. When both agents were added simultaneously, a diminution of PTX-induced tubulin polymerization was observed with increasing doses of VBL; a maximum reduction was achieved when equal concentrations were used. Examination of the tubulin pattern by immunofluorescence in MCF-7 breast cancer cells confirmed and extended our findings. Bundle formation followed treatment with PTX. Addition of increasing concentrations of VBL prevented bundling; however, the normal cytoskeletal architecture was not restored. Cytotoxicity studies carried out using the median dose effect principles and the combination index analysis showed synergism when VBL and PTX were administered sequentially and antagonism for simultaneous administration. Our results demonstrate changes in tubulin dynamics following drug treatment and provide a rationale for combined PTX/VBL therapy after careful evaluation of the schedule of administration.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9426691     DOI: 10.1002/(sici)1097-0215(19980105)75:1<57::aid-ijc10>3.0.co;2-a

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  14 in total

1.  Synthesis and discovery of water-soluble microtubule targeting agents that bind to the colchicine site on tubulin and circumvent Pgp mediated resistance.

Authors:  Aleem Gangjee; Ying Zhao; Lu Lin; Sudhir Raghavan; Elizabeth G Roberts; April L Risinger; Ernest Hamel; Susan L Mooberry
Journal:  J Med Chem       Date:  2010-10-25       Impact factor: 7.446

2.  Mitotic kinesin inhibitors induce mitotic arrest and cell death in Taxol-resistant and -sensitive cancer cells.

Authors:  Adam I Marcus; Ulf Peters; Shala L Thomas; Sarah Garrett; Amelia Zelnak; Tarun M Kapoor; Paraskevi Giannakakou
Journal:  J Biol Chem       Date:  2005-01-13       Impact factor: 5.157

3.  Anti-STMN1 therapy improves sensitivity to antimicrotubule drugs in esophageal squamous cell carcinoma.

Authors:  Shuai Wang; Javed Akhtar; Zhou Wang
Journal:  Tumour Biol       Date:  2015-05-06

4.  The synergistic combination of the farnesyl transferase inhibitor lonafarnib and paclitaxel enhances tubulin acetylation and requires a functional tubulin deacetylase.

Authors:  Adam I Marcus; Jun Zhou; Aurora O'Brate; Ernest Hamel; Jason Wong; Michael Nivens; Adel El-Naggar; Tso-Pang Yao; Fadlo R Khuri; Paraskevi Giannakakou
Journal:  Cancer Res       Date:  2005-05-01       Impact factor: 12.701

Review 5.  Microtubule-binding agents: a dynamic field of cancer therapeutics.

Authors:  Charles Dumontet; Mary Ann Jordan
Journal:  Nat Rev Drug Discov       Date:  2010-10       Impact factor: 84.694

6.  Antitumor effect of XCT790, an ERRα inverse agonist, on ERα-negative endometrial cancer cells.

Authors:  Tetsuya Kokabu; Taisuke Mori; Hiroshi Matsushima; Kaori Yoriki; Hisashi Kataoka; Yosuke Tarumi; Jo Kitawaki
Journal:  Cell Oncol (Dordr)       Date:  2019-01-31       Impact factor: 6.730

7.  Combination of albendazole and 2-methoxyestradiol significantly improves the survival of HCT-116 tumor-bearing nude mice.

Authors:  Anahid Ehteda; Peter Galettis; Krishna Pillai; David L Morris
Journal:  BMC Cancer       Date:  2013-02-23       Impact factor: 4.430

8.  Low-dose paclitaxel synergizes with oncolytic adenoviruses via mitotic slippage and apoptosis in ovarian cancer.

Authors:  C K Ingemarsdotter; S K Baird; C M Connell; D Öberg; G Halldén; I A McNeish
Journal:  Oncogene       Date:  2010-08-23       Impact factor: 9.867

9.  Colchitaxel, a coupled compound made from microtubule inhibitors colchicine and paclitaxel.

Authors:  Karunananda Bombuwala; Thomas Kinstle; Vladimir Popik; Sonal O Uppal; James B Olesen; Jose Viña; Carol A Heckman
Journal:  Beilstein J Org Chem       Date:  2006-06-30       Impact factor: 2.883

10.  A patient-derived stem cell model of hereditary spastic paraplegia with SPAST mutations.

Authors:  Greger Abrahamsen; Yongjun Fan; Nicholas Matigian; Gautam Wali; Bernadette Bellette; Ratneswary Sutharsan; Jyothy Raju; Stephen A Wood; David Veivers; Carolyn M Sue; Alan Mackay-Sim
Journal:  Dis Model Mech       Date:  2012-12-20       Impact factor: 5.758

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.